Phase 1 Refractory Leukemia Clinical Trials
5 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–5 of 5 trials
Recruiting
Phase 1Phase 2
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic LeukemiaLeukemiaRelapsed Leukemia+2 more
Jennifer R. Brown, MD, PhD64 enrolled1 locationNCT06644183
Recruiting
Phase 1Phase 2
A Study of Revumenib and Mezigdomide in People With Leukemia
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+5 more
Memorial Sloan Kettering Cancer Center52 enrolled10 locationsNCT07356154
Recruiting
Phase 1
Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia
Relapsed LeukemiaRefractory Leukemia
Beijing 302 Hospital5 enrolled1 locationNCT07297173
Recruiting
Phase 1Phase 2
Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Acute Myeloid LeukemiaRefractory LeukemiaRelapse Leukemia+1 more
Chongqing Precision Biotech Co., Ltd36 enrolled1 locationNCT06006403
Recruiting
Phase 1
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
CARRefractory LeukemiaLymphoblastic Leukemia in Children+4 more
National University Hospital, Singapore20 enrolled1 locationNCT05043571